Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Pharmaco-Kinesis Corporation Develops First Combinatorial Nano-Drug TNT™

  Pharmaco-Kinesis Corporation Develops First Combinatorial Nano-Drug TNT™

PKC Combines Temozolomide and Thalidomide Nanoparticles for Potential Drug
Therapy to Treat Gliomas and Other Cancers

Business Wire

LOS ANGELES -- April 30, 2013

Pharmaco-Kinesis Corporation (PKC), an advanced medical device company
developing smart implantable pumps and medications for local drug delivery,
today reported development of the first combinatorial nano-drug product
candidate, a combination of Temozolomide (Merck & Co.) and Thalidomide
(Celgene) nanoparticles to be tested for treatment of gliomas and other

PKC CEO Frank Adell shows sample of TNT(TM) Nano-Drug (Photo: Business Wire)

PKC CEO Frank Adell shows sample of TNT(TM) Nano-Drug (Photo: Business Wire)

Based on the collaboration with University of California, San Diego’s
Department of NanoEngineering at the Moores Cancer Center, PKC is planning
development and testing of the nano-droplet TNT™, a combination of
Temozolomide, an anti-cancer drug from Merck & Co., Inc., and Thalidomide, an
anti-cancer drug from Celgene Corporation, in a formulation with ratio of 50%
Temozolomide and 50% Thalidomide.

If this potentially groundbreaking achievement by PKC proves effective,
pharmaceutical companies may seek to use this technique in a manner, which
allows them simultaneously to dissolve at body temperature in their
nano-format. PKC believes 2,000 to 20,000 molecules of each type of drug can
be packaged in one nano-droplet and preliminary tests indicate that the ratio
of these different drugs can be precisely controlled. PKC intends that these
nano-droplets will be produced with special affinities for cancer cells,
attaching to and destroying such cells with enhanced efficacy compared to
traditional drug treatment. PKC has commenced in vivo lab tests of TNT™, and
preliminary results indicate that the nano-drug combination has substantially
more efficacy than formulations of these drugs currently in use by physicians.

PKC predicts that direct local site delivery will be required to achieve the
potentially high efficacy of the nano-drugs. PKC is in the process of
developing a microminiaturized Metronomic Biofeedback Pump Nano (MBPn)
version, a fully implantable infusion pump that enables programmable,
metronomic, local delivery and sampling via a multi-channel catheter that has
the potential to avoid elimination by the liver. PKC hopes that the MBPn will
increase therapeutic efficacy of drugs while reducing their side effects in
comparison with current systemic delivery methods.

“We are conducting ongoing development and testing in order to prove the
efficacy of delivering proprietary nano-droplet formulations of anti-cancer
medications using our MBP,” said Frank Adell, CEO of PKC. “If these tests are
successful, we believe PKC will produce a major advance in treating gliomas
and potentially other types of cancer as well.”

Photos/Multimedia Gallery Available:



Pharmaco-Kinesis Corporation
Daniel Saks, Senior VP Corporate Affairs
Sponsored Links
Sponsored Links